Product Pipeline

SBI Biotech strives for novel drug development targeting cancers and autoimmune diseases. We focus on development of molecule targeting drugs and immune modulation drugs with lower side effects and higher efficacies, based on our technologies on DC platform.

Pipeline Overview

Product Candidate Indication Partner
ILT7 (VIB7734) Myositis Viela Bio
SBI-9674 Autoimmune diseases
including SLE
Kyowa Kirin
SBI-3150 Autoimmune diseases caused
by pDCs/activated B cells
Asahi Kasei Pharma
GNKS356 (TLR antagonist) Psoriasis, Rheumatoid Arthritis,
IBD, SLE, etc.
Cdc7(AS-141/SRA141) Various cancers Carna Biosciences, Inc(*)

(*) After SBI Biotech has transferred intellectual property of Cdc7 inhibitor to Carna Biosciences, Inc. (CBS) in 2014, CBS entered into the licensing agreement with Sierra Oncology, Inc. SBI Biotech is to receive milestone payments along with the progress of development.

 Back to top